Albarad Immune Response 04 Study Notes

Foundations of the Adaptive Immune Response

  • The immune system operates through a highly coordinated series of defense mechanisms, broadly classified into innate (non-specific) and adaptive (specific) responses.

  • The adaptive immune response, particularly emphasized in the fourth stage of immunology curriculum under the Albarad framework, is characterized by its specificity, diversity, memory, and the ability to distinguish between self and non-self molecules.

  • Adaptive immunity is primarily mediated by lymphocytes, specifically B−lymphocytesB-lymphocytes (humoral immunity) and T−lymphocytesT-lymphocytes (cell-mediated immunity).

The Major Histocompatibility Complex (MHCMHC)

  • The MHCMHC is a genetic region encoding for glycoproteins that are essential for the presentation of antigens to T−cellsT-cells.

  • There are two primary classes of MHCMHC molecules involved in the adaptive immune response:

  • MHCMHC Class I (MHC−IMHC-I):

    • Found on the surface of almost all nucleated cells in the body.
    • Presents endogenous antigens (antigens derived from the cytoplasm, such as viral proteins or tumor antigens) to CD8+CD8^+ cytotoxic T−lymphocytesT-lymphocytes.
    • The structure consists of an alpha (α\alpha) chain with three domains (α1,α2,α3\alpha_1, \alpha_2, \alpha_3) and a non-covalently linked β2−microglobulin\beta_2-microglobulin.
    • The peptide-binding groove is formed by the α1\alpha_1 and α2\alpha_2 domains and typically accommodates peptides of 8−118-11 amino acids in length.
  • MHCMHC Class II (MHC−IIMHC-II):

    • Expressed primarily on professional antigen-presenting cells (APCsAPCs), such as dendritic cells, macrophages, and B−cellsB-cells.
    • Presents exogenous antigens (antigens internalized via endocytosis or phagocytosis) to CD4+CD4^+ helper T−lymphocytesT-lymphocytes.
    • The structure consists of two non-identical chains: an alpha (α\alpha) chain (α1,α2\alpha_1, \alpha_2) and a beta (β\beta) chain (β1,β2\beta_1, \beta_2).
    • The peptide-binding groove is formed by the α1\alpha_1 and β1\beta_1 domains and can accommodate longer peptides, usually between 10−3010-30 amino acids.

Pathways of Antigen Processing and Presentation

  • The Endogenous Pathway (MHC−IMHC-I):

    • Intracellular proteins are tagged with ubiquitin and degraded by the proteasome into smaller peptides.
    • These peptides are transported into the Endoplasmic Reticulum (ERER) via the Transporter associated with Antigen Processing (TAPTAP) complex.
    • Within the ERER, peptides are loaded onto freshly synthesized MHC−IMHC-I molecules before being transported to the cell surface via the Golgi apparatus.
  • The Exogenous Pathway (MHC−IIMHC-II):

    • Extracellular pathogens are internalized into endosomes.
    • MHC−IIMHC-II molecules are synthesized in the ERER with an "invariant chain" (IiIi) blocking the binding groove to prevent premature peptide loading.
    • The MHC−II−IiMHC-II-Ii complex moves to the endosome, where the invariant chain is cleaved to leave the Class II-associated invariant chain peptide (CLIPCLIP).
    • The HLA−DMHLA-DM molecule facilitates the exchange of CLIPCLIP for the high-affinity exogenous peptide before the complex is displayed on the cell membrane.

T-Lymphocyte Activation and the Two-Signal Model

  • Activation of a naive T−cellT-cell requires multiple signals to prevent accidental activation against self-peptides.

  • Signal 1 (Antigen Recognition):

    • Occurs when the T−cellT-cell Receptor (TCRTCR) complex (including the CD3CD3 signaling unit) binds to the specific peptide presented on an MHCMHC molecule.
    • CD4CD4 acts as a co-receptor for MHC−IIMHC-II, while CD8CD8 acts as a co-receptor for MHC−IMHC-I.
  • Signal 2 (Co-stimulation):

    • Interaction between co-stimulatory molecules on the APCAPC and the T−cellT-cell.
    • A primary example is the binding of CD80/86CD80/86 (also known as B7.1/B7.2B7.1/B7.2) on the APCAPC to CD28CD28 on the T−cellT-cell.
    • In the absence of Signal 2, the T−cellT-cell may enter a state of anergy (unresponsiveness), which is a key mechanism of peripheral tolerance.
  • Signal 3 (Differentiation):

    • Cytokines produced by the APCAPC and the surrounding microenvironment determine the functional fate of the activated T−cellT-cell.

Functional Subsets of Helper T-Cells (THT_H)

  • Activated CD4+CD4^+ cells differentiate into distinct lineages based on cytokine signaling:

  • TH1T_H1 Cells:

    • Driven by Interleukin-12 (IL−12IL-12) and Interferon-gamma (IFN−γIFN-\gamma).
    • Primary function: Defense against intracellular pathogens (viruses, some bacteria).
    • Major cytokine produced: IFN−γIFN-\gamma, which activates macrophages.
  • TH2T_H2 Cells:

    • Driven by Interleukin-4 (IL−4IL-4).
    • Primary function: Defense against extracellular parasites (helminths) and involvement in allergic reactions.
    • Major cytokines produced: IL−4,IL−5, and IL−13IL-4, IL-5, \text{ and } IL-13.
  • TH17T_H17 Cells:

    • Driven by IL−6IL-6 and Transforming Growth Factor-beta (TGF−βTGF-\beta).
    • Primary function: Defense against extracellular bacteria and fungi; linked to inflammatory and autoimmune diseases.
    • Major cytokine produced: IL−17IL-17.
  • TregT_{reg} (Regulatory T-cells):

    • Characterized by the expression of the transcription factor Foxp3Foxp3.
    • Function: Suppress immune responses and maintain self-tolerance.
    • Major cytokines produced: IL−10IL-10 and TGF−βTGF-\beta.

Effector Mechanisms of Cytotoxic T-Lymphocytes (CTLsCTLs)

  • CD8+T−cellsCD8^+ T-cells recognize infected or transformed cells and induce apoptosis through two primary mechanisms:

  • Granzyme and Perforin Pathway:

    • CTLsCTLs release perforin, which creates pores in the target cell membrane.
    • Granzymes (proteases) enter through these pores to activate caspades, leading to programmed cell death.
  • Fas/FasLFas/FasL Interaction:

    • The FasFas Ligand (FasLFasL) on the CTLCTL binds to the FasFas receptor (also known as CD95CD95) on the target cell, triggering the extrinsic apoptosis pathway.